NCT03836209 2025-06-15Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaPrECOG, LLC.Phase 2 Active not recruiting181 enrolled 18 charts
NCT02927262 2024-11-26A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionAstellas Pharma IncPhase 2 Completed98 enrolled 17 charts